Eltrombopag: Is this "24 karat gold platelet" treatment for thrombocytopenia in cirrhosis associated with hepatitis C?

Hepatology

Volumn 47, Issue 4, 2008, Pages 1418-1421

  Zekry, Amany ^a   Freiman, John ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; PEGINTERFERON; PLACEBO; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; HEADACHE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 42249092059     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22300     Document Type: Article

References (24)

1. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000;95:2936-2939.
2. Liangpunsakul S, Ulmer BJ, Chalasani N. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci 2003;326:111-116.
3. Iga D, Tomimatsu M, Endo H, Ohkawa S, Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-alpha therapy: possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol 2005;75:417-423.
4. Weksler BB. Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007;26(Suppl 1):13-19.
5. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369:565-568.
6. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994;369:571-574.
7. Zeigler FC, de Sauvage F, Widmer HR, Keller GA, Donahue C, Schreiber RD, et al. In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 1994;84:4045-4052.
8. Pallard C, Gouilleux F, Benit L, Cocault L, Souyri M, Levy D, et al. Thrombopoietin activates a STAT5-like factor in hematopoietic cells. EMBO J 1995;14:2847-2856.
9. Wolber EM, Jelkmann W. Thrombopoietin: the novel hepatic hormone. News Physiol Sci 2002;17:6-10.
10. Nagata Y, Shozaki Y, Nagahisa H, Nagasawa T, Abe T, Todokoro K. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during Thrombocytopenia and thrombocytosis. Thromb Haemost 1997;77:808-814.
11. Kuter DJ. The physiology of platelet production. Stem Cells 1996;14(Suppl 1):88-101.
12. Yang C, Li YC, Kuter DJ. The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol 1999;105:478-485.
13. Giannini E, Botta F, Borro P, Malfatti F, Fumagalli A, Testa E, et al. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. Am J Gastroenterol 2003;98:2516-2520.
14. Giannini E, Borro P, Botta F, Fumagalli A, Malfatti F, Podesta E, et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol 2002;37:572-577.
15. Wolber EM, Ganschow R, Burdelski M, Jelkmann W. Hepatic thrombopoietin mRNA levels in acute and chronic liver failure of childhood. HEPATOLOGY 1999;29:1739-1742.
16. Shiota G, Okubo M, Kawasaki H, Tahara T. Interferon increases serum thrombopoietin in patients with chronic hepatitis C. Br J Haematol 1997;97:340-342.
17. Peck-Radosavljevic M, Wichlas M, Pidlich J, Sims P, Meng G, Zacherl J, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. HEPATOLOGY 1998;28:1424-1429.
18. Peck-Radosavljevic M, Wichlas M, Zacherl J, Stiegler G, Stohlawetz P, Fuchsjager M, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000;95:795-801.
19. Rios R, Sangro B, Herrero I, Quiroga J, Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 2005;100:1311-1316.
20. Hidaka H, Kokubu S, Saigenji K, Isobe Y, Maeda T. Restoration of thrombopoietin production after partial splenic embolization leads to resolution of thrombocytopenia in liver cirrhosis. Hepatol Res 2002;23:265.
21. Sezai S, Kamisaka K, Ikegami F, Usuki K, Urabe A, Tahara T, et al. Regulation of hepatic thrombopoietin production by portal hemodynamics in liver cirrhosis. Am J Gastroenterol 1998;93:80-82.
22. Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000;96:2093-2099.
23. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-2236.
24. Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007;46:206-212.